BC Extra | Nov 13, 2019
Company News

Nov. 12 Company Quick Takes: Clinical hold for Solid Bio; plus Foamix-Menlo, Chi-Med, RegeneRx and Actelion

Solid Bio shares sag on news of latest clinical hold  FDA has placed a clinical hold on the Phase I/II IGNITE DMD study of gene therapy SGT-001 from Solid Biosciences Inc. (NASDAQ:SLDB) after one of...
BioCentury | Jun 29, 2019
Finance

All eyes on new modality launches, cancer and rare disease data in 3Q19

While the typical summer lull means fewer catalysts in the third quarter, investors will be keeping a close eye on launches of new modality drugs. Of special interest to multiple buysiders is the launch of...
BioCentury | May 24, 2019
Finance

How Europe’s hotspots of innovation could fuel its rise as a global player in new modalities

It is clear that Europe has hotspots of innovation that are discovering and developing the next wave of new therapeutic modalities. Nearly every category of new modality has a European champion, with clusters forming around...
BioCentury | Jan 5, 2019
Finance

Ready to launch

  The proposed $74 billion takeout of Celgene Corp. by Bristol-Myers Squibb Co. will not shift buysider attention away from upcoming and maturing drug launches heading into 2019, with plenty to track following a record...
BC Extra | Nov 28, 2018
Company News

Management tracks: PolarityTE and Foamix hire first chief commercial officers

Regenerative biomaterial company PolarityTE Inc. (NASDAQ:PTE) hired Matt Kemp as chief commercial officer, a newly created position. He was CCO at Dendreon Pharmaceuticals LLC, now owned by Chinese conglomerate Sanpower Group Co. Ltd. (Nanjing, China)....
BC Week In Review | Nov 9, 2018
Clinical News

Foamix planning NDA for minocycline foam to treat rosacea

Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX) plans to submit an NDA to FDA next year for FMX103 to treat moderate to severe papulopustular rosacea after the product met the co-primary endpoints in a pair of Phase III...
BC Extra | Nov 7, 2018
Clinical News

Foamix planning NDA for minocycline foam to treat rosacea

Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX) plans to submit an NDA to FDA next year for FMX103 to treat moderate to severe papulopustular rosacea after the product met the co-primary endpoints in a pair of Phase III...
BioCentury | Oct 6, 2018
Finance

Seeking validation

The final stretch of the year offers clinical catalysts and early launch data that could validate investments in hot immuno-oncology targets and large untapped markets. Late-stage readouts from Vertex Pharmaceuticals Inc. in cystic fibrosis and...
BC Week In Review | Sep 14, 2018
Clinical News

Foamix's minocycline foam meets in third Phase III for acne

Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX) reported on Sept. 11 that FMX101 met the co-primary endpoints in the Phase III FX2017-22 trial to treat moderate to severe acne. By year end, the company plans to submit an...
BC Extra | Sep 14, 2018
Financial News

Foamix raises $70M following Phase III acne readout

Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX) raised $70 million through the sale of 11.7 million shares at $6 in a follow-on underwritten by BofA Merrill Lynch, Cowen, Barclays and Cantor Fitzgerald. The price is a tiny discount...
Items per page:
1 - 10 of 62
BC Extra | Nov 13, 2019
Company News

Nov. 12 Company Quick Takes: Clinical hold for Solid Bio; plus Foamix-Menlo, Chi-Med, RegeneRx and Actelion

Solid Bio shares sag on news of latest clinical hold  FDA has placed a clinical hold on the Phase I/II IGNITE DMD study of gene therapy SGT-001 from Solid Biosciences Inc. (NASDAQ:SLDB) after one of...
BioCentury | Jun 29, 2019
Finance

All eyes on new modality launches, cancer and rare disease data in 3Q19

While the typical summer lull means fewer catalysts in the third quarter, investors will be keeping a close eye on launches of new modality drugs. Of special interest to multiple buysiders is the launch of...
BioCentury | May 24, 2019
Finance

How Europe’s hotspots of innovation could fuel its rise as a global player in new modalities

It is clear that Europe has hotspots of innovation that are discovering and developing the next wave of new therapeutic modalities. Nearly every category of new modality has a European champion, with clusters forming around...
BioCentury | Jan 5, 2019
Finance

Ready to launch

  The proposed $74 billion takeout of Celgene Corp. by Bristol-Myers Squibb Co. will not shift buysider attention away from upcoming and maturing drug launches heading into 2019, with plenty to track following a record...
BC Extra | Nov 28, 2018
Company News

Management tracks: PolarityTE and Foamix hire first chief commercial officers

Regenerative biomaterial company PolarityTE Inc. (NASDAQ:PTE) hired Matt Kemp as chief commercial officer, a newly created position. He was CCO at Dendreon Pharmaceuticals LLC, now owned by Chinese conglomerate Sanpower Group Co. Ltd. (Nanjing, China)....
BC Week In Review | Nov 9, 2018
Clinical News

Foamix planning NDA for minocycline foam to treat rosacea

Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX) plans to submit an NDA to FDA next year for FMX103 to treat moderate to severe papulopustular rosacea after the product met the co-primary endpoints in a pair of Phase III...
BC Extra | Nov 7, 2018
Clinical News

Foamix planning NDA for minocycline foam to treat rosacea

Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX) plans to submit an NDA to FDA next year for FMX103 to treat moderate to severe papulopustular rosacea after the product met the co-primary endpoints in a pair of Phase III...
BioCentury | Oct 6, 2018
Finance

Seeking validation

The final stretch of the year offers clinical catalysts and early launch data that could validate investments in hot immuno-oncology targets and large untapped markets. Late-stage readouts from Vertex Pharmaceuticals Inc. in cystic fibrosis and...
BC Week In Review | Sep 14, 2018
Clinical News

Foamix's minocycline foam meets in third Phase III for acne

Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX) reported on Sept. 11 that FMX101 met the co-primary endpoints in the Phase III FX2017-22 trial to treat moderate to severe acne. By year end, the company plans to submit an...
BC Extra | Sep 14, 2018
Financial News

Foamix raises $70M following Phase III acne readout

Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX) raised $70 million through the sale of 11.7 million shares at $6 in a follow-on underwritten by BofA Merrill Lynch, Cowen, Barclays and Cantor Fitzgerald. The price is a tiny discount...
Items per page:
1 - 10 of 62